NASDAQ:MIST

Milestone Pharmaceuticals Stock Forecast, Price & News

$5.30
-0.11 (-2.03 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.23
Now: $5.30
$5.47
50-Day Range
$5.29
MA: $6.58
$7.52
52-Week Range
$2.05
Now: $5.30
$11.40
Volume58,214 shs
Average Volume106,749 shs
Market Capitalization$158.18 million
P/E RatioN/A
Dividend YieldN/A
Beta4.2
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
Milestone Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MIST
CUSIPN/A
CIKN/A
Phone514-336-0444
Employees28
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.69 per share

Profitability

Net Income$-55,230,000.00

Miscellaneous

Market Cap$158.18 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Milestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings Results
March 30, 2021 |  americanbankingnews.com
MIST Jan 2021 7.500 call
December 28, 2020 |  uk.finance.yahoo.com
MIST Jan 2021 7.500 put
December 28, 2020 |  uk.finance.yahoo.com
MIST Jan 2021 10.000 call
December 24, 2020 |  uk.finance.yahoo.com
Milestone Pharmaceuticals EPS beats by $0.09
November 13, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

701st out of 2,021 stocks

Pharmaceutical Preparations Industry

338th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$5.30
-0.11 (-2.03 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

Is Milestone Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Milestone Pharmaceuticals stock.
View analyst ratings for Milestone Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Milestone Pharmaceuticals?

Wall Street analysts have given Milestone Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Milestone Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Milestone Pharmaceuticals
.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its earnings results on Sunday, March, 28th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.28.
View Milestone Pharmaceuticals' earnings history
.

How has Milestone Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MIST shares have decreased by 73.3% and is now trading at $5.34.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MIST?

5 brokerages have issued 1 year target prices for Milestone Pharmaceuticals' shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Milestone Pharmaceuticals' stock price to reach $14.60 in the next twelve months. This suggests a possible upside of 173.4% from the stock's current price.
View analysts' price targets for Milestone Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 53, Pay $784.99k)
  • Mr. Amit Hasija, CFO & Exec. VP of Corp. Devel. (Age 48, Pay $409.25k)
  • Dr. Francis Plat, Chief Medical Officer (Age 63, Pay $579.09k)
  • Dr. Philippe Douville, Founder, Strategic Advisor & Member of Scientific Advisory Board (Age 59)
  • Mr. Jeff Nelson, Chief Operating Officer
  • Dr. Philip T. Sager, Chief Medical Advisor & Member of the Scientific Advisory Board (Age 65)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 57)

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $5.34.

How much money does Milestone Pharmaceuticals make?

Milestone Pharmaceuticals has a market capitalization of $159.38 million. The company earns $-55,230,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis.

How many employees does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals employs 28 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

Where are Milestone Pharmaceuticals' headquarters?

Milestone Pharmaceuticals is headquartered at 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.